Wire · opportunities
FDA Approves Brepocitinib, First Oral Drug for Dermatomyositis in Adults
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA approved brepocitinib (Lisraya) as the first oral treatment for adult dermatomyositis, supported by positive phase 3 trial results showing significant clinical improvements and steroid-sparing benefits. The drug received orphan and priority review designations, marking a regulatory milestone for this rare autoimmune disease with few treatment options.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.
◆ ◆ The Wire takeaway
You are now able to offer an oral, steroid-sparing treatment option for dermatomyositis patients, opening new market access in rare autoimmune diseases and reducing dependency on high-dose corticosteroids. This shifts the treatment baseline and could redefine competitive positioning for therapies in this niche.
◆ Coverage
10 sources · first reported 27 Aug 2026 · latest 2 Sep 2026
◆ Topics